Free Trial
→ Why Iran May Only Be the First Move (From Behind the Markets) (Ad)tc pixel
NASDAQ:TIL

Instil Bio Earnings Date & Estimates

Instil Bio logo
$6.42 -0.05 (-0.70%)
As of 02:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Instil Bio is estimated to report earnings on Monday, November 16, 2026.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Instil Bio

Instil Bio is expected to post earnings of -$0.17 per share. In the same quarter a year earlier Instil Bio reported -$2.01 per share. Instil Bio last reported on August 13, 2026, posting -$0.63 per share and missing the -$0.35 consensus estimate. Instil Bio has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.17
Prior-Year EPS
-$2.01

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.63 (Missed by -$0.28)
EPS Beat Rate
3 of last 8 quarters

Prepare for the Earnings Call

Instil Bio Earnings FAQ

Instil Bio (NASDAQ:TIL) is estimated to report earnings on Monday, November 16, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Instil Bio to post earnings of -$0.17 per share for the quarter.

Instil Bio Earnings Headlines

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3345000/0/en/instil-bio-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html
Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)
July 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4922696-iovance-the-worst-may-be-behind-this-til-pioneer-upgrading-to-buy
The warning signs most investors see too late
Dr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.tc pixel
November 10 at 1:00 AM  |  Weiss Ratings (Ad)
Instil Bio Shareholders Back Directors and Auditor at Meeting
June 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/instil-bio-shareholders-back-directors-and-auditor-at-meeting?utm_source=marketbeat.com&utm_medium=referral
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/15/3295719/0/en/instil-bio-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html
Instil Bio (TIL) Price Target Increased by 24.53% to 67.32
April 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/instil-bio-til-price-target-increased-by-2453-to-6732/ar-AA20uMby
See More Instil Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Instil Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Instil Bio and other key companies, straight to your email.

About Instil Bio

Instil Bio (NASDAQ:TIL) is a clinical-stage biotechnology company focused on developing novel T-cell therapies for the treatment of cancer. The company’s research centers on tumor-infiltrating lymphocytes (TILs), immune cells that can recognize and attack cancer cells within tumors.

Instil Bio is developing engineered TIL programs intended to improve the ability of these cells to persist, function, and target solid tumors. Its pipeline has included investigational therapies such as ITIL-306, an engineered TIL product designed to target CD70-expressing cancers, along with other early-stage cell therapy candidates.

The company was founded in 2015 and became a publicly traded company in 2021. Instil Bio is headquartered in Dallas, Texas, and conducts research and development through its biotechnology operations. Its therapies remain investigational and are subject to clinical and regulatory evaluation.

View Instil Bio Profile
Earnings Tools